Apimeds Pharmaceuticals US, Inc. (APUS) - Net Assets
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has net assets worth $126.52 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($141.22 Million) and total liabilities ($14.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Apimeds Pharmaceuticals US, Inc. (APUS) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $126.52 Million |
| % of Total Assets | 89.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Apimeds Pharmaceuticals US, Inc. - Net Assets Trend (2021–2025)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Apimeds Pharmaceuticals US, Inc..
Annual Net Assets for Apimeds Pharmaceuticals US, Inc. (2021–2025)
The table below shows the annual net assets of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. Also explore APUS net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $153.35 Million | +11391.18% |
| 2024-12-31 | $-1.36 Million | -4361.31% |
| 2023-12-31 | $31.87K | +104.47% |
| 2022-12-31 | $-713.61K | -199.23% |
| 2021-12-31 | $-238.48K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apimeds Pharmaceuticals US, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 883748700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $125.76K | 0.08% |
| Other Components | $163.62 Million | 106.70% |
| Total Equity | $153.35 Million | 100.00% |
Apimeds Pharmaceuticals US, Inc. Competitors by Market Cap
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ostrom Climate Solutions Inc
V:COO
|
$2.48 Million |
|
PolyPlank publ AB
ST:POLY
|
$2.48 Million |
|
Serabi Gold PLC
LSE:SRB
|
$2.48 Million |
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
$2.48 Million |
|
Scout Security Ltd
AU:SCT
|
$2.47 Million |
|
John Wood Group PLC
LSE:WG
|
$2.47 Million |
|
Clean & Carbon Energy S.A.
WAR:CCE
|
$2.47 Million |
|
CL8 Holdings Ltd
AU:CL8
|
$2.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apimeds Pharmaceuticals US, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,358,121 to 153,347,827, a change of 154,705,948.
- Net loss of 6,001,137 reduced equity.
- New share issuances of 11,629,727 increased equity.
- Other factors increased equity by 149,077,358.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.00 Million | -3.91% |
| Share Issuances | $11.63 Million | +7.58% |
| Other Changes | $149.08 Million | +97.22% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Apimeds Pharmaceuticals US, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.19 | $1.64 | x |
| 2022-12-31 | $-5.62 | $1.64 | x |
| 2023-12-31 | $0.25 | $1.64 | x |
| 2024-12-31 | $-10.70 | $1.64 | x |
| 2025-12-31 | $140.92 | $1.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apimeds Pharmaceuticals US, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-3.91%) is above the historical average (-488.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.00 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-597.31K |
| 2023 | -2440.13% | 0.00% | 0.00x | 13.24x | $-780.88K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.25 Million |
| 2025 | -3.91% | 0.00% | 0.00x | 1.07x | $-21.34 Million |
Industry Comparison
This section compares Apimeds Pharmaceuticals US, Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $290,420,616
- Average return on equity (ROE) among peers: -51.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | $126.52 Million | 0.00% | 0.12x | $2.47 Million |
| Aurora Cannabis Inc (ACB) | $1.08 Million | -29.24% | 0.07x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $140.89 Million | 0.00% | 0.10x | $138.64 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $-30.58 Million | 0.00% | 0.00x | $241.89 Million |
| Alkermes Plc (ALKS) | $1.11 Billion | -4.33% | 0.82x | $7.72 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $3.58 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $5.80 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.00 Million | -54.00% | 0.38x | $279.44 Million |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.